| [1] |
Chen G, Zhang J, Teng W, Luo Y, Ji X. FDX1 inhibits thyroid cancer malignant progression by inducing cuprotosis. Heliyon, 2023, 9(8): e18655
|
| [2] |
Chen J, Cao W, Li Y, Zhu J. Comprehensive analysis of the expression level, prognostic value, and immune infiltration of cuproptosis-related genes in human breast cancer. Medicine (Baltimore), 2024, 103(42): e40132
|
| [3] |
Dai L, Zhou P, Lyu L, Jiang S. Systematic analysis based on the cuproptosis-related genes identifies ferredoxin 1 as an immune regulator and therapeutic target for glioblastoma. Bmc Cancer, 2023, 23(1): 1249
|
| [4] |
Ding D, Wang D, Qin Y. A cuproptosis-related gene signature and associated regulatory axis in stomach adenocarcinoma based on bioinformatics analysis. Medicine (Baltimore), 2023, 102(30): e34230
|
| [5] |
Dreishpoon MB, Bick NR, Petrova B, Warui DM, Cameron A, Booker SJ, Tsvetkov P. FDX1 regulates cellular protein lipoylation through direct binding to LIAS. Journal Of Biological Chemistry, 2023, 299(9): 105046
|
| [6] |
Du R, Li J, Li F, Mi L, Dionigi G, Sun H, Liang N. Estimating disease-free survival of thyroid cancer based on novel cuprotosis-related gene model. Front Endocrinol (Lausanne), 2023, 14: 1209172
|
| [7] |
Ewen KM, Kleser M, Bernhardt R. Adrenodoxin: the archetype of vertebrate-type [2Fe-2S] cluster ferredoxins. Biochimica Et Biophysica Acta, 2011, 1814(1): 111-125
|
| [8] |
Gao S, Ge H, Gao L, Gao Y, Tang S, Li Y, Chen W. Silk Fibroin Nanoparticles for Enhanced Cuproptosis and Immunotherapy in Pancreatic Cancer Treatment. Adv Sci (Weinh), 2025, 12(18): e2417676
|
| [9] |
Gao W, He X, Huangfu Q, Xie Y, Chen K, Sun C, Wang B. A novel cuproptosis-related prognostic gene signature in adrenocortical carcinoma. Journal Of Clinical Laboratory Analysis, 2023, 37(21–22): e24981
|
| [10] |
Guo X, He X, Chen W, Zhou J, Lyu Z, Li Z, Li Y. Long non-coding RNA SNHG7 as a key driver of colorectal cancer proliferation and metastasis by inhibiting cuproptosis. European Journal Of Medical Research, 2025, 30(1): 557
|
| [11] |
Guo Z, Chen D, Yao L, Sun Y, Li D, Le J, Deng G. The molecular mechanism and therapeutic landscape of copper and cuproptosis in cancer. Signal Transduct Target Ther, 2025, 10(1): 149
|
| [12] |
Hashimoto, T., Tsubota, K., Hatabi, K., & Hosoi, Y. (2025). FDX1 Regulates the Phosphorylation of ATM, DNA-PKcs Akt, and EGFR and Affects Radioresistance Under Severe Hypoxia in the Glioblastoma Cell Line T98G. International Journal Of Molecular Sciences, 26(7). https://doi.org/10.3390/ijms26073378
|
| [13] |
He S, Peng W, Hu X, Chen Y. Molecular function validation and prognostic value analysis of the cuproptosis-related gene ferredoxin 1 in papillary thyroid carcinoma. Scientific Reports, 2025, 15(1): 26845
|
| [14] |
Hu Y, Liu H, Tan X, Wu X. Knocking Down Ferredoxin 1 Inhibits the Progression of Colorectal Cancer and Regulates Cuproptosis via Mediating the Hippo Signaling Pathway. Molecular Carcinogenesis, 2025, 64(5): 911-922
|
| [15] |
Huang W, Wu Y, Zhu J, Luo N, Wang C, Liu S, Cheng Z. Pan-cancer integrated bioinformatics analysis reveals cuproptosis related gene FDX1 is a potential prognostic and immunotherapeutic biomarker for lower-grade gliomas. Frontiers in Molecular Biosciences, 2023, 10: 963639
|
| [16] |
Huang X, Wang T, Ye J, Feng H, Zhang X, Ma X, Zhang X. FDX1 expression predicts favourable prognosis in clear cell renal cell carcinoma identified by bioinformatics and tissue microarray analysis. Frontiers In Genetics, 2022, 13: 994741
|
| [17] |
Huang XX, Xie CK, Mo YC, Li W, Wu YD, Li ZY, Chen S. Targeting SERPINB3-MAPK axis-mediated cuproptosis resistance enhances the response to antitumor immunotherapy. Molecular Cancer, 2025
|
| [18] |
Jia G, Li J, Jiang M, Liu N, Ding N, Jiang X, Zhang Y. Unraveling the miR-144-3p/PUMA pathway: a novel regulator of FDX1-mediated cuproptosis in colorectal cancer. Cell Oncol (Dordr), 2025, 48(6): 1693-1710
|
| [19] |
Jiang, A., Ye, J., Zhou, Y., Zhu, B., Lu, J., Ge, S., & Cai, C. (2023a). Copper Death Inducer, FDX1, as a Prognostic Biomarker Reshaping Tumor Immunity in Clear Cell Renal Cell Carcinoma. Cells, 12(3). https://doi.org/10.3390/cells12030349
|
| [20] |
Jiang C, Li X, Wan S, Ji S, Wang Q, Hu S, Zhang P. Copper-Doped Polydopamine Nanoparticles-Mediated GSH/GPX4-Depleted Ferroptosis and Cuproptosis Sensitizes Lung Tumor to Checkpoint Blockade Immunotherapy. Small (Weinheim An Der Bergstrasse, Germany), 2025, 21(23): e2503208
|
| [21] |
Jiang Z, Sha G, Zhang W, Zhang Z, Liu T, Wang D, Tang D. The huge potential of targeting copper status in the treatment of colorectal cancer. Clinical & Translational Oncology, 2023, 25(7): 1977-1990
|
| [22] |
Li C, Chen T, Li Y, Zhou C, Du J, Li X, Cui H. Impact of diabetes and metformin on cuproptosis and ferroptosis in breast cancer patients: an immunohistochemical analysis. Discov Oncol, 2025, 16(1): 634
|
| [23] |
Li J, Cao X, Zhang L, Liu A, Liu S, Chen F, Liu J. Anti-FDX1 Autoantibody as a Potential Biomarker for Non-Small Cell Lung Cancer Detection. Cancer Epidemiology, Biomarkers & Prevention, 2025, 34(3): 439-447
|
| [24] |
Li L, Leng W, Chen J, Li S, Lei B, Zhang H, Zhao H. Identification of a copper metabolism-related gene signature for predicting prognosis and immune response in glioma. Cancer Medicine, 2023, 12(8): 10123-10137
|
| [25] |
Li X, Dai Z, Liu J, Sun Z, Li N, Jiao G, Cao H. Characterization of the functional effects of ferredoxin 1 as a cuproptosis biomarker in cancer. Frontiers In Genetics, 2022, 13: 969856
|
| [26] |
Liao Y, Wang D, Gu C, Wang X, Zhu S, Zheng Z, Gu Z. A cuproptosis nanocapsule for cancer radiotherapy. Nature Nanotechnology, 2024, 19(12): 1892-1902
|
| [27] |
Lill R, Muhlenhoff U. Iron-sulfur protein biogenesis in eukaryotes: components and mechanisms. Annual Review Of Cell And Developmental Biology, 2006, 22: 457-486
|
| [28] |
Lin J, Yin Y, Cao J, Zhang Y, Chen J, Chen R, Xie D. NUDT21 lactylation reprograms alternative polyadenylation to promote cuproptosis resistance. Cell Discov, 2025, 11(1): 52
|
| [29] |
Liu M, Ren X, Gong Z. Corin: a dual inhibitor for KDM1A/HDAC1, suppresses hepatocellular carcinoma by triggering cuproptosis. Clin Exp Med, 2025, 26(1): 33
|
| [30] |
Liu M, Wu S, Wu H, Zhou Y, Zhang X, Zhu D, Jiang J. Ferredoxin 1: a gatekeeper in halting lung adenocarcinoma progression through activation of the GPRIN2 signaling pathway. J Transl Med, 2024, 22(1): 510
|
| [31] |
Liu S, Lv S, Li X, Lu W, Chen S. The signature genes of cuproptosis associates with tumor immune microenvironment and predicts prognosis in kidney renal clear cell carcinoma. Frontiers In Oncology, 2024, 14: 1409620
|
| [32] |
Liu X, Qu H, Li J, Sun X, Wang Z, Wang D, Li X. p53 enhances elesclomol-Cu-induced cuproptosis in hepatocellular carcinoma via FDXR-mediated FDX1 upregulation. Frontiers In Oncology, 2025, 15: 1584811
|
| [33] |
Liu Z, Miao J. Prognostic and immunological role of FDX1 in pan-cancer: an in-silico analysis. Scientific Reports, 2023, 13(1): 7926
|
| [34] |
Lu, H., Liang, J., He, X., Ye, H., Ruan, C., Shao, H., & Li, Y. (2023). A Novel Oncogenic Role of FDX1 in Human Melanoma Related to PD-L1 Immune Checkpoint. International Journal Of Molecular Sciences, 24(11). https://doi.org/10.3390/ijms24119182
|
| [35] |
Ma J, Zhang Y, Sun Z, Guo H, Li X, Cai J, Zhang L. LncRNA PVT1 promotes cuproptosis through transcriptional activation of FDX1 in colorectal cancer. Redox Biology, 2025, 85: 103722
|
| [36] |
Pan S, Song C, Meng H, Li N, Li D, Hao B, Geng Q. Identification of cuproptosis-related subtypes in lung adenocarcinoma and its potential significance. Frontiers In Pharmacology, 2022, 13: 934722
|
| [37] |
Qian S, Liu J, Liao W, Wang F. METTL3 promotes non-small-cell lung cancer growth and metastasis by inhibiting FDX1 through copper death-associated pri-miR-21-5p maturation. Epigenomics, 2023, 15(23): 1237-1255
|
| [38] |
Qin L, Lv Z, Luo B, Yu J, Li M, Jing R, Li J. Hypoxia-induced autophagy attenuates ferredoxin 1-mediated cuproptosis in colorectal cancer cells. Human And Experimental Toxicology, 2025, 44: 9603271251335393
|
| [39] |
Quan Y, Li W, Yan R, Cheng J, Xu H, Chen L. Tumor cuproptosis and immune infiltration improve survival of patients with hepatocellular carcinoma with a high expression of ferredoxin 1. Frontiers In Oncology, 2023, 13: 1168769
|
| [40] |
Ran XM, Xiao H, Tang YX, Jin X, Tang X, Zhang J, Tang ZZ. The effect of cuproptosis-relevant genes on the immune infiltration and metabolism of gynecological oncology by multiply analysis and experiments validation. Scientific Reports, 2023, 13(1): 19474
|
| [41] |
Ren J, Su T, Ding J, Chen F, Mo J, Li J, Wu S. Chlorophyllin exerts synergistic anti-tumor effect with gemcitabine in pancreatic cancer by inducing cuproptosis. Molecular Medicine, 2025, 31(1): 126
|
| [42] |
Schulz V, Basu S, Freibert SA, Webert H, Boss L, Muhlenhoff U, Lill R. Functional spectrum and specificity of mitochondrial ferredoxins FDX1 and FDX2. Nature Chemical Biology, 2023, 19(2): 206-217
|
| [43] |
Schulz V, Freibert SA, Boss L, Mühlenhoff U, Stehling O, Lill R. Mitochondrial [2Fe-2S] ferredoxins: new functions for old dogs Vinzent Schulz. Febs Letters, 2023, 597(1): 102-121
|
| [44] |
Sheftel AD, Stehling O, Pierik AJ, Elsasser HP, Muhlenhoff U, Webert H, Lill R. Humans possess two mitochondrial ferredoxins, Fdx1 and Fdx2, with distinct roles in steroidogenesis, heme, and Fe/S cluster biosynthesis. Proc Natl Acad Sci U S A, 2010, 107(26): 11775-11780
|
| [45] |
Strushkevich N, MacKenzie F, Cherkesova T, Grabovec I, Usanov S, Park HW. Structural basis for pregnenolone biosynthesis by the mitochondrial monooxygenase system. Proc Natl Acad Sci U S A, 2011, 108(25): 10139-10143
|
| [46] |
Sun H, Chen Q, Zhang X, Chen M, Dai J, Yan M. Cuproptosis-Related Gene FDX1 Induces Malignant Progression and Immune Suppression in Triple-Negative Breast Cancer. Biochemical Genetics, 2025
|
| [47] |
Sun L, Zhang Y, Yang B, Sun S, Zhang P, Luo Z, Huang C. Lactylation of METTL16 promotes cuproptosis via m(6)A-modification on FDX1 mRNA in gastric cancer. Nature Communications, 2023, 14(1): 6523
|
| [48] |
Sun Z, Xu H, Lu G, Yang C, Gao X, Zhang J, Li J. AKT1 Phosphorylates FDX1 to Promote Cuproptosis Resistance in Triple-Negative Breast Cancer. Adv Sci (Weinh), 2025, 12(17): e2408106
|
| [49] |
Takahashi, R., Kamizaki, K., Yamanaka, K., Terai, Y., & Minami, Y. (2023). Expression of Ferredoxin1 in cisplatin–resistant ovarian cancer cells confers their resistance against ferroptosis induced by cisplatin. Oncology Reports, 49(6). https://doi.org/10.3892/or.2023.8561
|
| [50] |
Tang D, Kroemer G, Kang R. Targeting cuproplasia and cuproptosis in cancer. Nature Reviews. Clinical Oncology, 2024, 21(5): 370-388
|
| [51] |
Tao X, Wang H, Wang Q, Wang C, Shao CW, Jin Y, Zhang W. Marine Natural Product Chagosendine C Induces Cuproptosis in Colorectal Cancer Cells by Targeting FDX1. Journal Of The American Chemical Society, 2025, 147(41): 37089-37103
|
| [52] |
Tsvetkov P, Coy S, Petrova B, Dreishpoon M, Verma A, Abdusamad M, Golub TR. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science, 2022, 375(6586): 1254-1261
|
| [53] |
Wang C, Guo J, Zhang Y, Zhou S, Jiang B. Cuproptosis-Related Gene FDX1 Suppresses the Growth and Progression of Colorectal Cancer by Retarding EMT Progress. Biochemical Genetics, 2025, 63(1): 775-788
|
| [54] |
Wang F, Fang L, Fan C. METTL3 Represses FDX1 Expression Through m6A Methylation to Facilitate the Malignant Progression of Breast Cancer. Journal Of Biochemical And Molecular Toxicology, 2025, 39(12): e70629
|
| [55] |
Wang L, Cao Y, Guo W, Xu J. High expression of cuproptosis-related gene FDX1 in relation to good prognosis and immune cells infiltration in colon adenocarcinoma (COAD). Journal Of Cancer Research And Clinical Oncology, 2023, 149(1): 15-24
|
| [56] |
Wang T, Liu Y, Li Q, Luo Y, Liu D, Li B. Cuproptosis-related gene FDX1 expression correlates with the prognosis and tumor immune microenvironment in clear cell renal cell carcinoma. Frontiers In Immunology, 2022, 13: 999823
|
| [57] |
Wang W, Lu K, Jiang X, Wei Q, Zhu L, Wang X, Feng L. Ferroptosis inducers enhanced cuproptosis induced by copper ionophores in primary liver cancer. Journal Of Experimental & Clinical Cancer Research : Cr, 2023, 42(1): 142
|
| [58] |
Wang Y, Qiao S, Wang P, Li M, Ma X, Wang H, Dong J. Copper’s new role in cancer: how cuproptosis-related genes could revolutionize glioma treatment. Bmc Cancer, 2025, 25(1): 859
|
| [59] |
Wu A, Yin N, Li Z, Zhang X, Zhang Z, Zhong T, Dong J. FDX1 facilitates elesclomol-induced cuproptosis and promotes glioblastoma development via transcription factor NFKB1. Biochemical Pharmacology, 2025, 241: 117186
|
| [60] |
Wu C, Long L, Wang M, Shen L, Hu J, Tang H, Chen Y. Copper-mediated SEC14L3 promotes cuproptosis to inhibit hepatocellular carcinoma growth via ERK/YY1/FDX1 axis. Commun Biol, 2025, 8(1): 658
|
| [61] |
Xiao C, Yang L, Jin L, Lin W, Zhang F, Huang S, Huang Z. Prognostic and immunological role of cuproptosis-related protein FDX1 in pan-cancer. Frontiers In Genetics, 2022, 13: 962028
|
| [62] |
Xie, M., Cheng, B., Yu, S., He, Y., Cao, Y., Zhou, T., & Wang, R. (2022). Cuproptosis-Related MiR-21-5p/FDX1 Axis in Clear Cell Renal Cell Carcinoma and Its Potential Impact on Tumor Microenvironment. Cells, 12(1). https://doi.org/10.3390/cells12010173
|
| [63] |
Xie XZ, Zuo L, Huang W, Fan QM, Weng YY, Yao WD, Jin JQ. FDX1 as a novel biomarker and treatment target for stomach adenocarcinoma. World J Gastrointest Surg, 2024, 16(6): 1803-1824
|
| [64] |
Xu H, Zhao Q, Cai D, Chen X, Zhou X, Gao Y, Nan A. o8G-modified circKIAA1797 promotes lung cancer development by inhibiting cuproptosis. Journal Of Experimental & Clinical Cancer Research : Cr, 2025, 44(1): 110
|
| [65] |
Xu J, Hu Z, Cao H, Zhang H, Luo P, Zhang J, Li J. Multi-omics pan-cancer study of cuproptosis core gene FDX1 and its role in kidney renal clear cell carcinoma. Frontiers In Immunology, 2022, 13: 981764
|
| [66] |
Xu W, Liao S, Hu Y, Huang Y, Zhou J. Upregulation of miR-3130-5p Enhances Hepatocellular Carcinoma Growth by Suppressing Ferredoxin 1: miR-3130-5p Enhances HCC Growth via Inhibiting FDX1. Current Molecular Pharmacology, 2025
|
| [67] |
Yan JN, Guo LH, Zhu DP, Ye GL, Shao YF, Zhou HX. Clinical significance and potential application of cuproptosis-related genes in gastric cancer. World Journal Of Gastrointestinal Oncology, 2023, 15(7): 1200-1214
|
| [68] |
Yang B, Pan M, Tao T, Chen K, Kong D, Hao J, Gong H. Tanshinone IIA promotes METTL3/METTL14-mediated FDX1 m6A modification to induce cuproptosis in bladder cancer. Toxicol Res (Camb), 2025, 14(4): tfaf123
|
| [69] |
Yang L, Pi P, Zhang M, Jiang Y, Wu T, Qing L, Liang B. Copper ionophore complex ES-Cu synergizes with quercetin to target FDX1, promote cuproptosis, and reverse lenvatinib resistance in hepatocellular carcinoma cells. Journal Of Advanced Research, 2025
|
| [70] |
Yang W, Wu C, Jiang C, Jing T, Lu M, Xia D, Peng D. FDX1 overexpression inhibits the growth and metastasis of clear cell renal cell carcinoma by upregulating FMR1 expression. Cell Death Discov, 2025, 11(1): 115
|
| [71] |
Yang Z, Su W, Wei X, Pan Y, Xing M, Niu L, Yao B. Hypoxia inducible factor-1alpha drives cancer resistance to cuproptosis. Cancer Cell, 2025, 43(5): 937-954e939
|
| [72] |
Ye Z, Song Y, Zhu M, Zheng F, Qin W, Li X, Li A. Assessing the prognostic and therapeutic value of cuproptosis-related genes in colon adenocarcinoma patients. Front Cell Dev Biol, 2025, 13: 1550982
|
| [73] |
You Z, He J, Gao Z. Comprehensive analysis of the role of cuproptosis-related genes in the prognosis and immune infiltration of adrenocortical Carcinoma. Heliyon, 2024, 10(1): e23661
|
| [74] |
Zeng, S., Zhang, H., Zhang, D., Hu, X., & Song, L. (2022). Prognostic, Clinicopathological, and Function of Key Cuproptosis Regulator FDX1 in Clear Cell Renal Cell Carcinoma. Genes (Basel), 13(10). https://doi.org/10.3390/genes13101725
|
| [75] |
Zhang C, Zeng Y, Guo X, Shen H, Zhang J, Wang K, Huang S. Pan-cancer analyses confirmed the cuproptosis-related gene FDX1 as an immunotherapy predictor and prognostic biomarker. Frontiers In Genetics, 2022, 13: 923737
|
| [76] |
Zhang G, Chen X, Fang J, Tai P, Chen A, Cao K. Cuproptosis status affects treatment options about immunotherapy and targeted therapy for patients with kidney renal clear cell carcinoma. Frontiers In Immunology, 2022, 13: 954440
|
| [77] |
Zhang G, Shen L, Li Z, Zhao Y. FDX1 serves as a prognostic biomarker and promotes glioma progression by regulating the immune response. Aging (Albany NY), 2023, 15(11): 4963-4985
|
| [78] |
Zhang, K., Yang, W., Zhang, Z., Ma, K., Li, L., Xu, Y., & Gong, K. (2022c). A Novel Cuproptosis-Related Prognostic Model and the Hub Gene FDX1 Predict the Prognosis and Correlate with Immune Infiltration in Clear Cell Renal Cell Carcinoma. Journal of Oncology, 2022(2124088). https://doi.org/10.1155/2022/2124088
|
| [79] |
Zhang MJ, Shi M, Yu Y, Ou R, Ge RS, Duan P. Curcuminoid PBPD induces cuproptosis and endoplasmic reticulum stress in cervical cancer via the Notch1/RBP-J/NRF2/FDX1 pathway. Molecular Carcinogenesis, 2024, 63(8): 1449-1466
|
| [80] |
Zhang WT, Gong YM, Zhang CY, Pan JS, Huang T, Li YX. A Novel Cuprotosis-Related Gene FDX1 Signature for Overall Survival Prediction in Clear Cell Renal Cell Carcinoma Patients. Biomed Research International, 2022, 2022: 9196540
|
| [81] |
Zhang Y, Xie W, Li J, Liang Z, Zhou X, Tan Z, Yang R. Precision targeted melanoma therapy via cuproptosis/chemodynamic and chemotherapy: An engineering MCHS-CuMOF nanodelivery system. Biomater Adv, 2025, 171: 214228
|
| [82] |
Zhao Q, Yu M, Du X, Li Y, Lv J, Jiang X, Yang X. The Role of Cuproptosis Key Factor FDX1 in Gastric Cancer. Current Pharmaceutical Biotechnology, 2024, 26(1): 132-142
|
| [83] |
Zhao Y, Zheng R, Luo K, Zhao H, Xiang W. The CEBPA/FDX1 axis elevates sensitivity to cuproptosis in lung adenocarcinoma cells. Biochimica Et Biophysica Acta - General Subjects, 2026, 1870(1): 130872
|
| [84] |
Zou Q, Chen Y, Liu D, Du Q, Zhang C, Mai Q, Liu J. Cuproptosis inhibits tumor progression and enhances cisplatin toxicity in ovarian cancer. The Faseb Journal, 2025, 39(6): e70484
|
| [85] |
Zuo X, Lei Y, Ou S, Yuan X, Shi P, Li Q, Xu Y. Integration of cuproptosis-related gene signatures in stomach adenocarcinoma: implications for prognostic prediction and therapeutic strategies in cancer drug resistance. Discov Oncol, 2025, 16(1): 885
|
Funding
National Natural Science Foundation of China(82371788)
Science, Technology and Innovation Commission of Shenzhen Municipality(KQTD20210811090219022)
RIGHTS & PERMISSIONS
Shenzhen University School of Medicine; Fondazione Istituto FIRC di Oncologia Molecolare
PDF
